108x Filetype PDF File size 2.32 MB Source: bncp.ac.in
FINAL YEAR UNIVERSITY EXAMINATION 2019-2020 Final Year B. Pharm. Semester VIII Subject: Pharmaceutical Regulatory Affairs (BPH_E_809_T) PRACTICE QUESTION BANK 1. Select the responsibility/s of RA personnel a. To analyze the content of the active ingredient in the formulation b. Work with federal, state and local governing agencies to get the approval for drug c. To undertake stability studies of the drug products d. To supervise the production of the formulation 2. How many drugs can be imported under single Form11 license? a. 20 b. 5 c. 10 d. 15 3. List of approved drugs and their associated IPR is available in ________ a. Pink book b. Orange book c. Red book d. Black book 4. Identify the relevant regulatory body in USFDA for approval of drugs. a. BLA b. IND c. CBER d. CDER 5. In US the Orphan Drug Exclusivity (ODE) last for ……years a. 5 b. 6 c. 7 d. 8 6. In Europe, variations are classified as Type-IA for ….........change a. Minor b. Major c. Moderate d. Relative 7. …….. are the committees related to EU Regulations a. TGA b. CDER c. CBER d. COMP 8. The “Certificate of Suitability” as per EU guidelines is valid for…... years from the date when the original certificate was granted. a. 5 b. 10 c. 15 d. 20 9. CTD is divided into …..modules a. 3 b. 4 c. 5 d. 6 10. Schedule ….....of the D&C Act 1940 and Rules 1945 deals with the guidelines for Good Manufacturing Practices a. Y b. M c. P d. X 11. The entry in Batch Manufacturing Record is done by a. Quality control department b. Quality assurance department c. Warehouse department d. Production department 12. In pharmacovigilance the term ADR stands for _________ a. Adverse Drug Reaction b. Adverse Dose Reaction c. Absolute Drug Reaction d. Absolute Dose Reaction 13. BCS classification for Class III drugs is a. High solubility high permeability b. Low solubility high permeability c. High solubility low permeability d. Low solubility Low permeability 14. As per ANDA requirements the bioequivalence of test to reference formulation is _________ a. 80-120% b. 100-150% c. 70-130% d. 70-80% 15. Which of the following is regulatory authority of Australia a. Pharmaceutical and Medical Devices Agency b. Therapeutic Goods Administration c. Medicines and Healthcare Products Regulatory Agency d. Central Drug Standard Control Organization 16. Which of the following is an International regulatory authority for drug regulation a. CDSCO b. US-FDA c. WHO d. EMA 17. The oldest quality control laboratory of the Drug Control Authorities in India is a. Central Drugs Testing Laboratory, Kolkata b. Central Drugs Testing Laboratory (CDTL) Chennai , Tamil Nadu c. Central Drugs Testing Laboratory (CDTL) Hyderabad, AP d. Central Drugs Testing Laboratory (CDTL), Mumbai 18. Which of the following is a branch of CDL- a. New Delhi b. Kolkata c. Faridabad d. Bangalore 19. Indian Pharmacopoeia Commission headquarter is located at a. Delhi b. Mumbai c. Hyderabad d. Ghaziabad 20. Central drug Testing Laboratory is located at _____________ a. Kasauli b. Delhi c. Bangalore d. Lucknow 21. The 1st edition of Indian Pharmacopoeia was published in the year a. 1966 b. 1955 c. 1950 d. 1960 22. The objective of FDA- India office is- a. To ensure the safety, quality, and effectiveness of medical products and food produced in India for export to the United States. b. Approval of medical products for marketing in India c. Import of drug in India for test and examination d. Manufacture of drugs in USA for the purpose of export to India 23. The chairman of Indian Pharmacopoeial commission is- a. Chairman-Scientific Body b. The Drugs Controller General c. Directorate General of Health Services d. The Secretary, Ministry of Health and Family Welfare 24. In PCT, patent application enters national phase at- a. 12 months b. 24 months c. 30 months d. 36 months 25. The term of patent is valid for the period of 20 years from the
no reviews yet
Please Login to review.